Company presentation scheduled on Tuesday, March 4th at 9:10am ET –– EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal ...
Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on ...
CAMBRIDGE, Mass., February 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback